IDiyas

For the Inventor, By the Inventor

Parma, Italy

Anna Maria Capelli

USPTO Granted Patents = 11 

 

 

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:

goldMedal11 out of 328 
 
Chiesi Farmaceutici S.p.a.
 patents

Years Active: 2014-2021

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 11147812 - Tyrosine analogues derivatives as Rho-kinase inhibitors (2021-10-19),
2. 10954236 - Tyrosine amide derivatives as Rho-Kinase inhibitors (2021-03-23),
3. 10584128 - Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors (2020-03-10),
4. 10501461 - Tyrosine amide derivatives as Rho-kinase inhibitors (2019-12-10),
5. 10189844 - Pyrazole derivatives as phosphoinositide 3-kinases inhibitors (2019-01-29),
6. 9968604 - Chromene derivatives as phoshoinositide 3-kinases inhibitors (2018-05-15),
7. 9745308 - Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors (2017-08-29),
8. 9527869 - Indolizine derivatives as phoshoinositide 3-kinases inhibitors (2016-12-27),
9. 9321776 - Isochromene derivatives as phoshoinositide 3-kinases inhibitors (2016-04-26),
10. 8835412 - Isoxazolidine derivatives (2014-09-16),
11. 8710037 - Pyrrolidine derivatives, pharmaceutical compositions containing the same, and methods of using the same (2014-04-29),

Title: The Innovative Contributions of Anna Maria Capelli

Introduction

Anna Maria Capelli is a distinguished inventor based in Parma, Italy. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target Rho-kinase enzymes. With a total of 11 patents to her name, her work has the potential to impact the treatment of various pulmonary diseases.

Latest Patents

Among her latest patents are two notable inventions. The first is titled "Tyrosine analogues derivatives as Rho-kinase inhibitors." This invention relates to compounds that inhibit Rho Kinase and are particularly useful in treating disorders associated with ROCK enzyme mechanisms. These disorders include pulmonary diseases such as asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH). The second patent, "Tyrosine amide derivatives as Rho-Kinase inhibitors," describes bicyclic dihydropyrimidine-carboxamide compounds that also inhibit Rho Kinase and may be used for similar therapeutic applications.

Career Highlights

Anna Maria Capelli is currently employed at Chiesi Farmaceutici S.p.a., where she continues to innovate and develop new pharmaceutical solutions. Her expertise in the field has led to advancements that could significantly improve patient outcomes in respiratory health.

Collaborations

Throughout her career, Anna has collaborated with talented individuals such as Alessandro Accetta and Matteo Biagetti. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Anna Maria Capelli's contributions to the field of pharmaceuticals, particularly in the development of Rho-kinase inhibitors, highlight her innovative spirit and dedication to improving health outcomes. Her work continues to pave the way for advancements in the treatment of pulmonary diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…